Computational chemistry and structural biology

Ajax Therapeutics is focused on developing innovative therapies for myeloproliferative neoplasms (MPNs) by leveraging advanced computational chemistry and structural biology techniques. The company is particularly dedicated to creating next-generation JAK2 inhibitors, specifically Type II JAK2 inhibitors, which are designed to bind more selectively to the JAK2 kinase. This approach aims to enhance therapeutic efficacy and reduce the mutant JAK2 allele burden that contributes to disease progression, addressing the limitations of existing Type I JAK2 inhibitors like ruxolitinib, which can allow for disease persistence due to continued JAK/STAT signaling.

In collaboration with Schrödinger, Inc., Ajax Therapeutics utilizes state-of-the-art molecular simulation software to optimize the design of small molecules with desired functional activities and drug-like properties. Their lead candidate, AJ1-10502, has shown promising preclinical results, demonstrating improved selectivity and efficacy compared to current therapies. This innovative approach not only aims to provide better treatment options for patients with MPNs but also seeks to establish Ajax as a leader in the development of targeted therapies that can significantly improve patient outcomes.

United States

Ajax Therapeutics is a biotechnology company developing precision therapies for blood cancers called hematologic malignancies. The company has a unique partnership with Schrödinger, Inc. to develop novel small molecules targeting cytokine signaling pathways for hematologic malignancies.

Ajax Therapeutics

Company Details